Diammonium Glycyrrhizinate Mitigates Liver Injury Via Inhibiting Proliferation Of NKT Cells And Promoting Proliferation Of Tregs

References

• Yuksel M, Wang Y, Tai N, et al. A novel “humanized mouse” model for autoimmune hepatitis and the association of gut microbiota with liver inflammation. Hepatology. 2015;62(5):1536–1550. doi:10.1002/hep.2799826185095
   PubMed Web of Science ®Google Scholar
• de Boer YS, van Gerven NM, Zwiers A, et al. Genome-wide association study identifies variants associated with autoimmune hepatitis type 1. Gastroenterology. 2014;147(2):443–452. doi:10.1053/j.gastro.2014.04.02224768677
   PubMed Web of Science ®Google Scholar
• Kirstein MM, Seibel E, Manns MP, et al. Prediction of short- and long-term outcome in patients with autoimmune hepatitis. J Hepatol. 2015;62(5):1524–1535. doi:10.1002/hep.27983
   Web of Science ®Google Scholar
• Wang QX, Yan L, Ma X. Autoimmune hepatitis in the Asia-Pacific area. J Clin Transl Hepatol. 2018;6(1):48–56. doi:10.14218/JCTH.2017.0003229577032
   PubMed Web of Science ®Google Scholar
• Heneghan MA, Yeoman A, Verma S, Smith AD, Longhi MS. Autoimmune hepatitis. Lancet. 2013;382:1433–1444. doi:10.1016/S0140-6736(12)62163-123768844
   PubMed Web of Science ®Google Scholar
• Ikeda A, Aoki N, Kido M, et al. Progression of autoimmune hepatitis is mediated by IL‐18‐producing dendritic cells and hepatic CXCL9 expression in mice. Hepatology. 2014;60:224–236. doi:10.1002/hep.2708724700550
   PubMed Web of Science ®Google Scholar
• Liberal R, Grant CR, Yuksel M, et al. Treg conditioning endows activated teff with suppressor function in autoimmune hepatitis/autoimmune sclerosing cholangitis. Hepatology. 2017;66(5):1570–1584. doi:10.1002/hep.2930728597951
   PubMed Web of Science ®Google Scholar
• Wang H, Yin S. Natural killer T cells in liver injury, inflammation and cancer. Expert Rev Gastroenterol Hepatol. 2015;9(8):1077–1085. doi:10.1586/17474124.2015.105673826068039
   PubMed Web of Science ®Google Scholar
• Bhattacharjee J, Kirby M, Softic S, et al. Hepatic natural killer T-cell and CD8+ T-cell signatures in mice with nonalcoholic steatohepatitis. Hepatol Commun. 2017;1(4):299–310. doi:10.1002/hep4.104129152605
   PubMed Web of Science ®Google Scholar
• Wolf M, Adili A, Piotrowitz K, et al. Metabolic activation of intrahepatic CD8+ T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes. Cancer Cell. 2014;26(4):549–564. doi:10.1016/j.ccell.2014.09.00325314080
   PubMed Web of Science ®Google Scholar
• Zheng W, Du S, Tian M, et al. Lepidium meyenii walp exhibits anti-inflammatory activity against ConA-induced acute hepatitis. Mediators Inflamm. 2018;2018:8982756. doi:10.1155/2018/898275630647537
   PubMed Web of Science ®Google Scholar
• Lu Y, Guo Y, Xu L, Li Y, Cao L. Foxp3 regulates ratio of Treg and NKT cells in a mouse model of asthma. Mol Cell Biochem. 2015;403(1–2):25–31. doi:10.1007/s11010-015-2333-225636804
   PubMed Web of Science ®Google Scholar
• Shi HJ, Song HB, Wang L, Xiao S-X, Bo K-P, Ma W. The synergy of diammonium glycyrrhizinate remarkably reduces the toxicity of oxymatrine in ICR mice. Biomed Pharmacother. 2018;97:19–25. doi:10.1016/j.biopha.2017.09.03929080454
   PubMed Web of Science ®Google Scholar
• Zhu X, Chen C, Ye D, et al. Diammonium glycyrrhizinate upregulates PGC-1α and protects against Aβ1–42-induced neurotoxicity. PLoS One. 2012;7(4):e35823. doi:10.1371/journal.pone.003582322540007
   PubMed Web of Science ®Google Scholar
• Jin J, Xiong T, Hou X, et al. Role of Nrf2 activation and NF-κB inhibition in valproic acid induced hepatotoxicity and in diammonium glycyrrhizinate induced protection in mice. Food Chem Toxicol. 2014;73:95–104. doi:10.1016/j.fct.2014.08.00925152329
   PubMed Web of Science ®Google Scholar
• Orlent H, Hansen BE, Willems M, et al. Biochemical and histological effects of 26 weeks of glycyrrhizin treatment in chronic hepatitis C: a randomized phase II trial. J Hepatol. 2006;45(4):539–546. doi:10.1016/j.jhep.2006.05.01516905220
   PubMed Web of Science ®Google Scholar
• Wang H, Fang ZZ, Meng R, et al. Glycyrrhizin and glycyrrhetinic acid inhibits alpha-naphthyl isothiocyanate-induced liver injury and bile acid cycle disruption. Toxicology. 2017;386:133–142. doi:10.1016/j.tox.2017.05.01228549656
   PubMed Web of Science ®Google Scholar
• Y W L, Hu YH, Zhu TT, Chu AZ, Zhu CL. Clinical efficacy of compound glycyrrhizin tablets in the treatment of children with nonalcoholic fatty liver disease. Zhongguo Dang Dai Er Ke Za Zhi. 2017;19(5):505–509.28506338
   PubMedGoogle Scholar
• Sun X, Duan X, Wang C, et al. Protective effects of glycyrrhizic acid against non-alcoholic fatty liver disease in mice. Eur J Pharmacol. 2017;806:75–82. doi:10.1016/j.ejphar.2017.04.02128414056
   PubMed Web of Science ®Google Scholar
• Yasui S, Fujiwara K, Tawada A, Fukuda Y, Nakano M, Yokosuka O. Efficacy of intravenous glycyrrhizin in the early stage of acute onset autoimmune hepatitis. Dig Dis Sci. 2011;56(12):3638–3647. doi:10.1007/s10620-011-1789-521681505
   PubMed Web of Science ®Google Scholar
• Zhang X, Yang H, Yue S, et al. The mTOR inhibition in concurrence with ERK1/2 activation is involved in excessive autophagy induced by glycyrrhizin in hepatocellular carcinoma. Cancer Me. 2017;6(8):1941–1951. doi:10.1002/cam4.1127
   Web of Science ®Google Scholar
• Li H, Guo D, Zhang L, Feng X. Glycyrrhizin attenuates histamine-mediated MUC5AC upregulation, inflammatory cytokine production, and aquaporin 5 downregulation through suppressing the NF-κB pathway in human nasal epithelial cells. Chem Biol Interact. 2018;285:21–26. doi:10.1016/j.cbi.2018.02.01029452068
   PubMed Web of Science ®Google Scholar
• Zhao X, Liu J, Yang S, et al. Diammonium glycyrrhizinate alleviates hepatopulmonary syndrome, via, restoring superoxide dismutase 3 activity in rats. Eur J Pharmacol. 2017;807:144–150. doi:10.1016/j.ejphar.2017.04.02528435094
   PubMed Web of Science ®Google Scholar
• Lei W, Huihui D, Yibo L, et al. Chinese medicine Bu Xu Hua Yu recipe for the regulation of Treg/Th17 ratio imbalance in autoimmune hepatitis. Evid Based Complement Alternat Med. 2015;2015(3):1–14. doi:10.1155/2015/459749
   Web of Science ®Google Scholar
• Taubert R, Hardtke-Wolenski M, Noyan F, et al. Intrahepatic regulatory T cells in autoimmune hepatitis are associated with treatment response and depleted with current therapies. J Hepatol. 2014;61(5):1106–1114. doi:10.1016/j.jhep.2014.05.03424882050
   PubMed Web of Science ®Google Scholar
• González-Amaro R, Cortés JR, Sánchez-Madrid F, Martín P. Is CD69 an effective brake to control inflammatory diseases? Trends Mol Med. 2013;19(10):625–632. doi:10.1016/j.molmed.2013.07.00623954168
   PubMed Web of Science ®Google Scholar
• Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1981;1(5):431–435. doi:10.1002/hep.18400105117308988
   PubMed Web of Science ®Google Scholar
• Park J, Kim H, Lee IS. The therapeutic effects of Yongdamsagan-tang on autoimmune hepatitis models. Biomed Pharmacother. 2017;94:244–255. doi:10.1016/j.biopha.2017.07.01528763748
   PubMed Web of Science ®Google Scholar
• W W L, J Y Y, H L X, Bao J-K. Concanavalin A: a potential anti-neoplastic agent targeting apoptosis, autophagy and anti-angiogenesis for cancer therapeutics. Biochem Biophys Res Commun. 2011;414(2):282–286. doi:10.1016/j.bbrc.2011.09.07221951850
   PubMed Web of Science ®Google Scholar
• Burger ML, Leung KK, Bennett MJ, Winoto A. T cell-specific inhibition of multiple apoptotic pathways blocks negative selection and causes autoimmunity. ELife. 2014;3(3):e03468. doi:10.7554/eLife.03468
   PubMed Web of Science ®Google Scholar
• Cortés JR, Sánchez-Díaz R, Bovolenta ER, et al. Maintenance of immune tolerance by Foxp3+ regulatory T cells requires CD69 expression. J Autoimmun. 2014;55(1):51–62. doi:10.1016/j.jaut.2014.05.00724934597
   PubMed Web of Science ®Google Scholar
• García-Monzón C, Moreno-Otero R, Pajares JM, et al. Expression of a novel T cell activation antigen on intrahepatic CD8+ T lymphocytes in viral chronic active hepatitis. Gastroenterology. 1990;98(4):1029–1035. doi:10.1016/0016-5085(90)90030-52138103
   PubMed Web of Science ®Google Scholar
• Hilda A, Roy-O’Reilly M, Spychala MS, et al. Sex differences in adipose tissue cd8+ t cells and regulatory t cells in middle-aged mice. Front Immunol. 2018;9:659. doi:10.3389/fimmu.2018.0065929670627
   PubMed Web of Science ®Google Scholar
• Murata K, Inami M, Hasegawa A, et al. CD69‐null mice protected from arthritis induced with anti‐type II collagen antibodies. Int Immunol. 2003;15(8):987–992. doi:10.1093/intimm/dxg00812882836
   PubMed Web of Science ®Google Scholar
• Miki-Hosokawa T, Hasegawa A, Iwamura C, et al. CD69 controls the pathogenesis of allergic airway inflammation. J Immunol. 2009;183(12):8203–8215. doi:10.4049/jimmunol.090083819923457
   PubMed Web of Science ®Google Scholar
• Han Y, Guo Q, Zhang M, Chen Z, Cao X. CD69+ CD4+ CD25− T cells, a new subset of regulatory T cells, suppress T cell proliferation through membrane-bound TGF-β1. J Immunol. 2009;182(1):111–120. doi:10.4049/jimmunol.182.1.11119109141
   PubMed Web of Science ®Google Scholar
• Zhao XS, Wang XH, Zhao XY, et al. Non-traditional CD4+ CD25− CD69+ regulatory T cells are correlated to leukemia relapse after allogeneic hematopoietic stem cell transplantation. J Transl Med. 2014;12(1):187. doi:10.1186/1479-5876-12-18724984576
   PubMed Web of Science ®Google Scholar
• Grage-Griebenow E, Jerg E, Gorys A, et al. L1CAM promotes enrichment of immunosuppressive T cells in human pancreatic cancer correlating with malignant progression. Mol Oncol. 2014;8(5):982–997. doi:10.1016/j.molonc.2014.03.00124746181
   PubMed Web of Science ®Google Scholar
• Zhao XY, Wang YT, Mo XD, et al. Higher frequency of regulatory T cells in granulocyte colony-stimulating factor (G-CSF)-primed bone marrow grafts compared with G-CSF-primed peripheral blood grafts. J Transl Med. 2015;13(1):145. doi:10.1186/s12967-015-0541-x25948100
   PubMed Web of Science ®Google Scholar
• Kumar V. NKT-cell subsets: promoters and protectors in inflammatory liver disease. J Hepatol. 2013;59(3):618–620. doi:10.1016/j.jhep.2013.02.03223669283
   PubMed Web of Science ®Google Scholar
• Kahraman A, Barreyro FJ, Bronk SF, et al. TRAIL mediates liver injury by the innate immune system in the bile duct–ligated mouse. Hepatology. 2008;47(4):1317–1330. doi:10.1002/hep.2213618220275
   PubMed Web of Science ®Google Scholar